CN115397514A - 大环化合物的治疗用途 - Google Patents

大环化合物的治疗用途 Download PDF

Info

Publication number
CN115397514A
CN115397514A CN202180023879.XA CN202180023879A CN115397514A CN 115397514 A CN115397514 A CN 115397514A CN 202180023879 A CN202180023879 A CN 202180023879A CN 115397514 A CN115397514 A CN 115397514A
Authority
CN
China
Prior art keywords
cancer
carcinoma
met
compound
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180023879.XA
Other languages
English (en)
Chinese (zh)
Inventor
B·W·默里
翟大勇
景荣·J·崔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tepu Pharmaceutical
Original Assignee
Tepu Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tepu Pharmaceutical filed Critical Tepu Pharmaceutical
Publication of CN115397514A publication Critical patent/CN115397514A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
CN202180023879.XA 2020-03-02 2021-03-01 大环化合物的治疗用途 Pending CN115397514A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062984159P 2020-03-02 2020-03-02
US62/984,159 2020-03-02
PCT/US2021/020255 WO2021178296A1 (en) 2020-03-02 2021-03-01 Therapeutic uses of macrocyclic compounds

Publications (1)

Publication Number Publication Date
CN115397514A true CN115397514A (zh) 2022-11-25

Family

ID=77613771

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180023879.XA Pending CN115397514A (zh) 2020-03-02 2021-03-01 大环化合物的治疗用途

Country Status (11)

Country Link
US (1) US20250262216A1 (https=)
EP (1) EP4114530A4 (https=)
JP (1) JP2023515687A (https=)
KR (1) KR20230022151A (https=)
CN (1) CN115397514A (https=)
AU (1) AU2021229457A1 (https=)
BR (1) BR112022017425A2 (https=)
CA (1) CA3174455A1 (https=)
IL (1) IL295938A (https=)
MX (1) MX2022010945A (https=)
WO (1) WO2021178296A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111902417B (zh) 2018-04-25 2023-07-28 北京普祺医药科技股份有限公司 一种二芳基巨环化合物、药物组合物以及其用途
US20240132517A1 (en) * 2021-02-10 2024-04-25 Goharmony Therapeutics (Shenzhen) Co., Ltd. Macrocyclic compound, pharmaceutical composition, and use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019023417A1 (en) * 2017-07-28 2019-01-31 Tp Therapeutics, Inc. MACROCYCLIC COMPOUNDS AND USES THEREOF

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS49779B (sr) * 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
ES2933350T3 (es) * 2014-01-24 2023-02-06 Turning Point Therapeutics Inc Macrociclos de diarilo como moduladores de proteína quinasas
RU2765181C2 (ru) * 2015-07-06 2022-01-26 Тёрнинг Поинт Терапьютикс, Инк. Полиморфная форма диарильного макроцикла
US10689400B2 (en) * 2016-07-28 2020-06-23 Turning Point Therapeutics, Inc. Macrocycle kinase inhibitors
CN114423762B (zh) * 2019-09-30 2024-03-29 浙江海正药业股份有限公司 大环类衍生物及其制备方法和用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019023417A1 (en) * 2017-07-28 2019-01-31 Tp Therapeutics, Inc. MACROCYCLIC COMPOUNDS AND USES THEREOF
CN111182903A (zh) * 2017-07-28 2020-05-19 特普医药公司 巨环化合物及其用途

Also Published As

Publication number Publication date
US20250262216A1 (en) 2025-08-21
AU2021229457A1 (en) 2022-10-20
IL295938A (en) 2022-10-01
BR112022017425A2 (pt) 2022-11-29
EP4114530A4 (en) 2024-04-17
MX2022010945A (es) 2022-10-07
CA3174455A1 (en) 2021-09-10
WO2021178296A1 (en) 2021-09-10
KR20230022151A (ko) 2023-02-14
JP2023515687A (ja) 2023-04-13
EP4114530A1 (en) 2023-01-11

Similar Documents

Publication Publication Date Title
US12310968B2 (en) Chiral diaryl macrocycles and uses thereof
TWI808958B (zh) 涉及二芳基巨環化合物之組合療法
KR20140043314A (ko) 이중 오로라 키나제／ｍｅｋ 억제제를 사용한 항암 치료법
EP4065395A1 (en) Combination therapy involving diaryl macrocyclic compounds
US10835525B2 (en) Method of inhibiting mutant C-KIT
US20140018372A1 (en) Crystalline form of a indolinone derivative and its use
CN115397514A (zh) 大环化合物的治疗用途
BR112017010849B1 (pt) Triazolopiridazina deuterada como um modulador quinase, seu processo de preparação, composição farmacêutica, usos e combinação
US20230241052A1 (en) Method of inhibiting mutant c-kit
WO2025201518A1 (en) Methods of treating tki-resistant and sdh-deficient gist
CN101010082A (zh) 米哚妥林用于治疗胃肠道基质瘤的用途
EP4229038A1 (en) Dosing regimens for cyclin-dependent kinase 7 (cdk7) inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20221125

WD01 Invention patent application deemed withdrawn after publication